These discoveries highlight the pivotal inhibitory function of the CD24-Siglec-E axis in metabolic dysfunctions and metaflammation, offering a potential immunotherapeutic approach for conditions like obesity, dyslipidemia, insulin resistance, and nonalcoholic steatohepatitis. Here, CD24 is linked to metabolic syndrome.